<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355705</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19092</org_study_id>
    <secondary_id>AR_MM_PI_007</secondary_id>
    <secondary_id>SU-05062011-7711</secondary_id>
    <secondary_id>HEMMYL0018</secondary_id>
    <nct_id>NCT01355705</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michaela Liedtke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if amrubicin is safe and useful for patients with multiple myeloma requiring
      additional treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES

        -  Establish the maximum tolerated dose (MTD) and toxicity profile for the combination of
           amrubicin with lenalidomide and dexamethasone in previously treated adult patients with
           multiple myeloma during Phase I

        -  Determine the combined rate of complete response (CR) and very good partial response
           (VGPR) for this combination in this population as defined by the International Myeloma
           Working Group Uniform Response Criteria (IMWGURC)

      SECONDARY OBJECTIVES

        -  Determine the overall response rate (CR, VGPR and PR)

        -  Assess additional evidence of ant-tumor activity as measured by duration of response
           (DOR), progression-free survival (PFS), time to tumor progression (TTP), and overall
           survival (OS)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria</measure>
    <time_frame>12 weeks</time_frame>
    <description>Modified International Myeloma Working Group Uniform Response Criteria:
Complete (CR)=
Negative for monoclonal protein (MP) in urine (U) and serum (S) +
No tissue plasmacytomas (PC) +
&lt;5% plasma cells (PCs) in marrow (M)
Stringent CR (sCR)= CR with normal light chain ratio+ no PCs in M
Near CR (nCR)= CR, except MP persists in U and S
Partial (PR)= S MP ≤50%, + U MP ≤90% or &lt;200 mg/24 hours (hr)
Very Good PR (VGPR)= in S MP ≤90%, + U MP &lt;100 mg/24 hr
Minimal (MR)=
S MP ≤51-75%, +
If light chain is excreted, reduced 50-89%/24 hr that is also &gt;200 mg/24 hr, +
No increase in lytic bone lesions
Progressive disease (PD)= any of:
S MP ≥125% and/or ≥+0.5 g/dL,
U MP ≥125% and/or ≥+200 mg/24 hr
New or increased bone lesions/PC
S calcium &gt;11.5 mg/dL (attributed to increased PCs)
PD after CR/sCR=
Reappearance of S or U MP
≥5% clonal PCs in M
New PC, lytic bone lesions, hypercalcemia
Stable Disease (SD)= Not CR, VGPR, MR, PR, or PD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>9 months</time_frame>
    <description>Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:
Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,
Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline
New or increased bone lesions or plasmacytomas
Serum calcium &gt; 11.5 mg/dL (attributed to increased plasma cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-next Treatment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amrubicin</intervention_name>
    <description>40, 60, or 80 mg/m2 intravenous (IV)</description>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <other_name>SM-5887</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>15 mg daily by mouth</description>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg weekly by mouth</description>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexpak Taperpak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81 or 325 mg daily by mouth</description>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>6 mg subcutaneous on Day 2</description>
    <arm_group_label>Amrubicin + Lenalidomide + Dexamethasone</arm_group_label>
    <other_name>Neulasta</other_name>
    <other_name>PEG-GCSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory multiple myeloma that has progressed following at least 1 prior
             therapy.

          -  Measurable disease defined as one of the following:

               -  Serum M-protein ≥ 1 g/dL

               -  Urine M-protein ≥ 200 mg/24 hours

          -  Received at least 1 prior line of systemic treatment that may have included
             lenalidomide and/or an anthracycline.

          -  No cytotoxic chemotherapy within 4 weeks prior to first dose of amrubicin. This
             interval may be reduced to 14 days for thalidomide, lenalidomide, bortezomib or
             corticosteroids, provided other entry criteria are met.

          -  Age ≥ 18 at the time of consent.

          -  Life expectancy of more than ≥ 3 months.

          -  No known central nervous system involvement by myeloma.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 at study
             registration during phase 1. Once safety is confirmed, ECOG performance status 0 to 2
             at study registration during phase 2.

          -  No poorly-controlled intercurrent illness.

          -  Platelets &gt; 100 x 10^9/L

          -  Hemoglobin &gt; 8.0g/dL

          -  Absolute neutrophil count (ANC) &gt;1.5 x 10^9/L

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x upper limit of
             normal (ULN)

          -  Total bilirubin ≤ 1.5 x ULN

          -  Calculated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula.

          -  Left ventricular ejection fraction (LVEF) ≥ 50% by Echocardiogram (ECHO) or multiple
             gate acquisition scan (MUGA)

          -  All study participants must be registered into the mandatory RevAssist program, and be
             willing and able to comply with the Requirements of RevAssist.

          -  Disease-free of prior malignancies for ≥ 5 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix
             or breast.

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 U/mL within 10 to 14 days and again within 24
             hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled
             within 7 days) and must either commit to continued abstinence from heterosexual
             intercourse or begin 2 acceptable methods of birth control, one highly effective
             method and one additional effective method at the same time, at least 28 days before
             she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing.

          -  Men must agree to use a latex condom during sexual contact with a FCBP even if they
             have had a successful vasectomy.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Able to take aspirin (81 or ≥ 25 mg) daily as prophylactic anticoagulation. Patients
             intolerant to aspirin may use warfarin or low molecular weight heparin (LMWH).
             Patients with previous thromboembolic event on lenalidomide or thalidomide may be
             started on warfarin or LMWH. Patients already taking warfarin or LMWH do not require
             additional aspirin..

          -  Lactating females must agree not to breast-feed while taking lenalidomide

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant or breastfeeding females.

          -  Any concurrent severe or uncontrolled medical disease which places the subject at
             unacceptable risk if he/she were to participate in the study or confounds the ability
             to interpret data from the study.

          -  Use of any other experimental drug or therapy within 28 days of first dose of
             amrubicin.

          -  Known hypersensitivity to thalidomide or lenalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  LVEF ≤ 50%.

          -  Concurrent use of other anti-cancer agents or treatments.

          -  Known positive for HIV, or infectious hepatitis, type B or C.

          -  Cranial radiotherapy ≤ 21 days prior to first dose of amrubicin; radiotherapy to all
             other areas ≤ 7 days prior to first dose of amrubicin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Liedtke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <results_first_submitted>January 11, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michaela Liedtke</investigator_full_name>
    <investigator_title>Assistant Professor Medicine/Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Amrubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amrubicin + Lenalidomide + Dexamethasone</title>
          <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amrubicin + Lenalidomide + Dexamethasone</title>
          <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria</title>
        <description>Modified International Myeloma Working Group Uniform Response Criteria:
Complete (CR)=
Negative for monoclonal protein (MP) in urine (U) and serum (S) +
No tissue plasmacytomas (PC) +
&lt;5% plasma cells (PCs) in marrow (M)
Stringent CR (sCR)= CR with normal light chain ratio+ no PCs in M
Near CR (nCR)= CR, except MP persists in U and S
Partial (PR)= S MP ≤50%, + U MP ≤90% or &lt;200 mg/24 hours (hr)
Very Good PR (VGPR)= in S MP ≤90%, + U MP &lt;100 mg/24 hr
Minimal (MR)=
S MP ≤51-75%, +
If light chain is excreted, reduced 50-89%/24 hr that is also &gt;200 mg/24 hr, +
No increase in lytic bone lesions
Progressive disease (PD)= any of:
S MP ≥125% and/or ≥+0.5 g/dL,
U MP ≥125% and/or ≥+200 mg/24 hr
New or increased bone lesions/PC
S calcium &gt;11.5 mg/dL (attributed to increased PCs)
PD after CR/sCR=
Reappearance of S or U MP
≥5% clonal PCs in M
New PC, lytic bone lesions, hypercalcemia
Stable Disease (SD)= Not CR, VGPR, MR, PR, or PD</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amrubicin + Lenalidomide + Dexamethasone</title>
            <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria</title>
          <description>Modified International Myeloma Working Group Uniform Response Criteria:
Complete (CR)=
Negative for monoclonal protein (MP) in urine (U) and serum (S) +
No tissue plasmacytomas (PC) +
&lt;5% plasma cells (PCs) in marrow (M)
Stringent CR (sCR)= CR with normal light chain ratio+ no PCs in M
Near CR (nCR)= CR, except MP persists in U and S
Partial (PR)= S MP ≤50%, + U MP ≤90% or &lt;200 mg/24 hours (hr)
Very Good PR (VGPR)= in S MP ≤90%, + U MP &lt;100 mg/24 hr
Minimal (MR)=
S MP ≤51-75%, +
If light chain is excreted, reduced 50-89%/24 hr that is also &gt;200 mg/24 hr, +
No increase in lytic bone lesions
Progressive disease (PD)= any of:
S MP ≥125% and/or ≥+0.5 g/dL,
U MP ≥125% and/or ≥+200 mg/24 hr
New or increased bone lesions/PC
S calcium &gt;11.5 mg/dL (attributed to increased PCs)
PD after CR/sCR=
Reappearance of S or U MP
≥5% clonal PCs in M
New PC, lytic bone lesions, hypercalcemia
Stable Disease (SD)= Not CR, VGPR, MR, PR, or PD</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR) rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good Partial Response (VGPR) Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total CR + VGPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR) Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response Rate (ORR = CR + VGPR + PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <time_frame>140 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amrubicin + Lenalidomide + Dexamethasone</title>
            <description>Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2
Amrubicin: 40, 60, or 80 mg/m2 intravenous (IV)
Lenalidomide: 15 mg daily by mouth
Dexamethasone: 40 mg weekly by mouth
Aspirin: 81 or 325 mg daily by mouth
Pegfilgrastim: 6 mg subcutaneous on Day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" lower_limit="129" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:
Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,
Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline
New or increased bone lesions or plasmacytomas
Serum calcium &gt; 11.5 mg/dL (attributed to increased plasma cells)</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amrubicin + Lenalidomide + Dexamethasone</title>
            <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:
Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,
Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline
New or increased bone lesions or plasmacytomas
Serum calcium &gt; 11.5 mg/dL (attributed to increased plasma cells)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="21" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-next Treatment</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amrubicin + Lenalidomide + Dexamethasone</title>
            <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-next Treatment</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="24" upper_limit="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks treatment, plus a minimum of 30 days follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amrubicin + Lenalidomide + Dexamethasone</title>
          <description>Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
Aspirin: 81 or 325 mg daily oral
Pegfilgrastim subcutaneous on Day 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progressive disease</sub_title>
                <description>Hospitalization for infusional chemotherapy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased ejection fraction (transient)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated AST/ALT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs host diseae (GvHD)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michaela Liedtke, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-498-6000</phone>
      <email>mliedtke@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

